<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Quantum Discovery Labs &#187; drug design</title>
	<atom:link href="http://q-pharm.com/category/drug-design/feed/" rel="self" type="application/rss+xml" />
	<link>http://q-pharm.com</link>
	<description>The drug discovery company</description>
	<lastBuildDate>Fri, 03 Feb 2012 10:47:43 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo</title>
		<link>http://q-pharm.com/2011/08/structure-based-drug-design-of-a-new-chemical-class-of-small-molecules-active-against-influenza-a-nucleoprotein-in-vitro-and-in-vivo/</link>
		<comments>http://q-pharm.com/2011/08/structure-based-drug-design-of-a-new-chemical-class-of-small-molecules-active-against-influenza-a-nucleoprotein-in-vitro-and-in-vivo/#comments</comments>
		<pubDate>Tue, 09 Aug 2011 06:18:11 +0000</pubDate>
		<dc:creator>Peter Fedichev, Quantum CTO</dc:creator>
				<category><![CDATA[docking]]></category>
		<category><![CDATA[drug design]]></category>
		<category><![CDATA[flue]]></category>
		<category><![CDATA[influenza]]></category>
		<category><![CDATA[publications]]></category>

		<guid isPermaLink="false">http://q-pharm.com/?p=419</guid>
		<description><![CDATA[The manuscript entitled &#8220;&#8221; by the Quantum Team has been accepted to PLoS Currents Influenza. The reference:
Fedichev, Peter; Timakhov, Roman; Pyrkov, Tim; Getmantsev, Evgeny; Vinnik, Andrey. Structure-based drug design of [...]


Related posts:<ol><li><a href='http://q-pharm.com/2011/04/influenza-matrix-m1-protein-inhibitors-show-promising-in-vivo-efficacy/' rel='bookmark' title='Influenza matrix M1 protein inhibitors show promising in-vivo efficacy'>Influenza matrix M1 protein inhibitors show promising in-vivo efficacy</a></li>
<li><a href='http://q-pharm.com/quantum-discovery-services/' rel='bookmark' title='Quantum Discovery Services'>Quantum Discovery Services</a></li>
<li><a href='http://q-pharm.com/2010/09/beefing-up-the-pipeline-new-leads-against-influenza-virus-identified/' rel='bookmark' title='Beefing up the pipeline: new leads against influenza virus identified'>Beefing up the pipeline: new leads against influenza virus identified</a></li>
<li><a href='http://q-pharm.com/2008/09/from-binding-data-to-pharmacokinetics-a-novel-approach-to-active-drug-absorbtion-prediction/' rel='bookmark' title='From binding data to pharmacokinetics: a novel approach to active drug absorbtion prediction'>From binding data to pharmacokinetics: a novel approach to active drug absorbtion prediction</a></li>
<li><a href='http://q-pharm.com/quantum-discovery-services/drug-design-drug-development-bioinformatics-and-preclinical-services/' rel='bookmark' title='Drug design, drug development, bioinformatics and preclinical services'>Drug design, drug development, bioinformatics and preclinical services</a></li>
</ol>

Related posts brought to you by <a href='http://yarpp.org'>Yet Another Related Posts Plugin</a>.]]></description>
		<wfw:commentRss>http://q-pharm.com/2011/08/structure-based-drug-design-of-a-new-chemical-class-of-small-molecules-active-against-influenza-a-nucleoprotein-in-vitro-and-in-vivo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1</title>
		<link>http://q-pharm.com/2011/06/new-map17-matrix-protein-inhibitors-display-broad-antiviral-activity-against-multiple-subtypes-of-hiv-1/</link>
		<comments>http://q-pharm.com/2011/06/new-map17-matrix-protein-inhibitors-display-broad-antiviral-activity-against-multiple-subtypes-of-hiv-1/#comments</comments>
		<pubDate>Tue, 21 Jun 2011 11:28:21 +0000</pubDate>
		<dc:creator>Peter Fedichev, Quantum CTO</dc:creator>
				<category><![CDATA[antiviral]]></category>
		<category><![CDATA[drug design]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[matrix proteins]]></category>

		<guid isPermaLink="false">http://q-pharm.com/?p=390</guid>
		<description><![CDATA[A key issue in the development of novel HIV drugs is their ability to inhibit the replication of genetically diverse isolates, especially those isolates from the most globally prevalent subtypes, [...]


Related posts:<ol><li><a href='http://q-pharm.com/2011/04/influenza-matrix-m1-protein-inhibitors-show-promising-in-vivo-efficacy/' rel='bookmark' title='Influenza matrix M1 protein inhibitors show promising in-vivo efficacy'>Influenza matrix M1 protein inhibitors show promising in-vivo efficacy</a></li>
<li><a href='http://q-pharm.com/2011/12/map17-hiv-matrix-protein-is-a-promising-target-for-drug-discovery/' rel='bookmark' title='MA/p17 HIV matrix protein is a promising target for drug discovery'>MA/p17 HIV matrix protein is a promising target for drug discovery</a></li>
<li><a href='http://q-pharm.com/2008/09/from-biological-spectra-multiple-protein-binding-data-to-pharmacological-profiling/' rel='bookmark' title='From Biological Spectra (multiple protein binding data) to pharmacological profiling!'>From Biological Spectra (multiple protein binding data) to pharmacological profiling!</a></li>
<li><a href='http://q-pharm.com/2009/11/do-we-need-those-nm-inhibitors/' rel='bookmark' title='Do we need those nM-inhibitors?'>Do we need those nM-inhibitors?</a></li>
<li><a href='http://q-pharm.com/2010/01/drug-resistance-evolution-in-action/' rel='bookmark' title='Drug resistance: evolution in action'>Drug resistance: evolution in action</a></li>
</ol>

Related posts brought to you by <a href='http://yarpp.org'>Yet Another Related Posts Plugin</a>.]]></description>
		<wfw:commentRss>http://q-pharm.com/2011/06/new-map17-matrix-protein-inhibitors-display-broad-antiviral-activity-against-multiple-subtypes-of-hiv-1/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Influenza matrix M1 protein inhibitors show promising in-vivo efficacy</title>
		<link>http://q-pharm.com/2011/04/influenza-matrix-m1-protein-inhibitors-show-promising-in-vivo-efficacy/</link>
		<comments>http://q-pharm.com/2011/04/influenza-matrix-m1-protein-inhibitors-show-promising-in-vivo-efficacy/#comments</comments>
		<pubDate>Sun, 10 Apr 2011 11:36:29 +0000</pubDate>
		<dc:creator>Peter Fedichev, Quantum CTO</dc:creator>
				<category><![CDATA[drug design]]></category>
		<category><![CDATA[flue]]></category>
		<category><![CDATA[influenza]]></category>
		<category><![CDATA[matrix proteins]]></category>

		<guid isPermaLink="false">http://q-pharm.com/?p=372</guid>
		<description><![CDATA[We have recently reported a discovery of novel potent inhibitors of influenza M1 matrix protein. The matrix protein structurally forms the protein envelope and has no close human analogues. That&#8217;s [...]


Related posts:<ol><li><a href='http://q-pharm.com/2011/06/new-map17-matrix-protein-inhibitors-display-broad-antiviral-activity-against-multiple-subtypes-of-hiv-1/' rel='bookmark' title='New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1'>New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1</a></li>
<li><a href='http://q-pharm.com/2011/12/map17-hiv-matrix-protein-is-a-promising-target-for-drug-discovery/' rel='bookmark' title='MA/p17 HIV matrix protein is a promising target for drug discovery'>MA/p17 HIV matrix protein is a promising target for drug discovery</a></li>
<li><a href='http://q-pharm.com/2011/08/structure-based-drug-design-of-a-new-chemical-class-of-small-molecules-active-against-influenza-a-nucleoprotein-in-vitro-and-in-vivo/' rel='bookmark' title='Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo'>Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo</a></li>
<li><a href='http://q-pharm.com/2010/09/beefing-up-the-pipeline-new-leads-against-influenza-virus-identified/' rel='bookmark' title='Beefing up the pipeline: new leads against influenza virus identified'>Beefing up the pipeline: new leads against influenza virus identified</a></li>
<li><a href='http://q-pharm.com/2008/01/ld50-vs-mrdd-whats-death-for-a-mice-is-good-enough-for-a-man/' rel='bookmark' title='LD50 vs. MRDD: what&#8217;s death for a mice is good enough for a man'>LD50 vs. MRDD: what&#8217;s death for a mice is good enough for a man</a></li>
</ol>

Related posts brought to you by <a href='http://yarpp.org'>Yet Another Related Posts Plugin</a>.]]></description>
		<wfw:commentRss>http://q-pharm.com/2011/04/influenza-matrix-m1-protein-inhibitors-show-promising-in-vivo-efficacy/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Beefing up the pipeline: new leads against influenza virus identified</title>
		<link>http://q-pharm.com/2010/09/beefing-up-the-pipeline-new-leads-against-influenza-virus-identified/</link>
		<comments>http://q-pharm.com/2010/09/beefing-up-the-pipeline-new-leads-against-influenza-virus-identified/#comments</comments>
		<pubDate>Mon, 20 Sep 2010 07:49:30 +0000</pubDate>
		<dc:creator>Peter Fedichev, Quantum CTO</dc:creator>
				<category><![CDATA[antiviral]]></category>
		<category><![CDATA[drug design]]></category>
		<category><![CDATA[flue]]></category>
		<category><![CDATA[influenza]]></category>
		<category><![CDATA[Quantum Software]]></category>

		<guid isPermaLink="false">http://q-pharm.com/?p=317</guid>
		<description><![CDATA[Quantum Free energy calculation software in combination with the docking tools and clustering tools to &#8220;zip&#8221; the amount of work required to screen the large libraries of the available chemical [...]


Related posts:<ol><li><a href='http://q-pharm.com/2011/04/influenza-matrix-m1-protein-inhibitors-show-promising-in-vivo-efficacy/' rel='bookmark' title='Influenza matrix M1 protein inhibitors show promising in-vivo efficacy'>Influenza matrix M1 protein inhibitors show promising in-vivo efficacy</a></li>
<li><a href='http://q-pharm.com/2011/08/structure-based-drug-design-of-a-new-chemical-class-of-small-molecules-active-against-influenza-a-nucleoprotein-in-vitro-and-in-vivo/' rel='bookmark' title='Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo'>Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo</a></li>
<li><a href='http://q-pharm.com/2010/07/new-inhibitors-of-reca-bacterial-sos-response-system-identified/' rel='bookmark' title='New inhibitors of RecA (bacterial SOS response system) identified.'>New inhibitors of RecA (bacterial SOS response system) identified.</a></li>
</ol>

Related posts brought to you by <a href='http://yarpp.org'>Yet Another Related Posts Plugin</a>.]]></description>
		<wfw:commentRss>http://q-pharm.com/2010/09/beefing-up-the-pipeline-new-leads-against-influenza-virus-identified/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New inhibitors of RecA (bacterial SOS response system) identified.</title>
		<link>http://q-pharm.com/2010/07/new-inhibitors-of-reca-bacterial-sos-response-system-identified/</link>
		<comments>http://q-pharm.com/2010/07/new-inhibitors-of-reca-bacterial-sos-response-system-identified/#comments</comments>
		<pubDate>Wed, 14 Jul 2010 07:29:11 +0000</pubDate>
		<dc:creator>Peter Fedichev, Quantum CTO</dc:creator>
				<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[drug design]]></category>
		<category><![CDATA[Quantum Software]]></category>
		<category><![CDATA[RecA]]></category>

		<guid isPermaLink="false">http://q-pharm.com/?p=306</guid>
		<description><![CDATA[Recently, RecA has established itself as a potential target for the development of antibacterial drugs. The dual function of recA allows bacteria both to control the damage associated with the [...]


Related posts:<ol><li><a href='http://q-pharm.com/2010/09/beefing-up-the-pipeline-new-leads-against-influenza-virus-identified/' rel='bookmark' title='Beefing up the pipeline: new leads against influenza virus identified'>Beefing up the pipeline: new leads against influenza virus identified</a></li>
</ol>

Related posts brought to you by <a href='http://yarpp.org'>Yet Another Related Posts Plugin</a>.]]></description>
		<wfw:commentRss>http://q-pharm.com/2010/07/new-inhibitors-of-reca-bacterial-sos-response-system-identified/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
	</channel>
</rss>

